Global Market Study on Non-infectious Macular Edema Treatment: Companies to Launch Biosimilars of First Anti-VEGF Lucentis by 2020

Non Infectious Macular Edema Treatment  Market
  • Published On : May-2018 |
  • Pages : 323 Pages |
  • Format : Non Infectious Macular Edema Treatment  Market Non Infectious Macular Edema Treatment  Market Non Infectious Macular Edema Treatment  Market Non Infectious Macular Edema Treatment  Market

Study unveils Corticosteroids as the fastest growing treatment for non-infectious macular edema in the global market

The global non-infectious macular edema treatment market is propelled with the increase in diabetes related complications and awareness in many regions towards eye-related diseases. The demand has an immediate impact on the increase in treatment options available for macular edema. The market comprises drug options like Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and others. Anti-VEGF is projected to continue holding the highest market share in the global market during the period of forecast. However, the Anti-VEGF market is expected to witness a steady decline in use with the growing awareness about various side-effects associated with this drug. Systemic immunomodulatory treatment will serve to diminish reliance on anti-VEGF. Corticosteroids are also expected to witness an exceptional rise in demand in the coming years. The Corticosteroids market is expected to rise at a stellar growth rate of 8.3% during the forecast period.

Approval of Intravitreal Implants and use of Immunosuppressants in the treatment of macular edema to trigger the growth of the market

Intravitreal Implants have been recently approved for the treatment of macular edema. Launch of three new products in 2014 viz., Eylea, Ozurdex and Iluvien, has led to the increased adoption of intravitreal medications in North America. The use of intravitreally injected medications was less common in North America and European countries as laser photocoagulation was the primary treatment before the launch of Lucentis in 2012. This increase in the adoption of Intravitreal therapies is a result of the launch of low dose high efficacy corticosteroid implants for Intravitreal use. Uptake of Intravitreal implants is increasing among patients, thus boosting the global demand for macular edema treatment.

Immunosuppressant therapies are widely utilized coupled with corticosteroids. These are generally added to the corticosteroid regimen to eliminate the need for high doses of systemic steroids, or used alone as steroid-sparing agents in situations where steroids cannot be tolerated. For e.g., the three immunomodulators methotrexate (Rheumatrex), azathioprine (Imuran) and mycophenolate mofetil (MMF, Cellcept) are more effective in achieving disease quiescence and are well-tolerated by patients. These work as an efficient treatment type in the cure of non-infectious macular edema thereby proliferating demand in the global market.

Availability of alternative treatment options and off-label drug use expected to hinder the growth of the global macular edema market

In several cases, patients and ophthalmologists prefer alternative treatments to anti-VEGF and corticosteroids to treat the various types of macular edema in patients. Anti-VEGF and corticosteroids require repeated injection of costly drugs. Majority of patients do not comply with the treatment schedule and tend to miss injections. If patients are left untreated for more than six months, DME causes irreversible damage to the photoreceptor and permanent loss of vision. This makes the population look for alternative options in the market. Similarly, there are also many counterfeit and off label drugs available in the global market. The launch of biosimilars for some of the blockbuster anti-VEGF agents is also expected to decrease overall market opportunity for the growth of branded and patented drugs throughout the world.

Global Healthcare Sector Outlook

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

  • Current expenditure on health, % of gross domestic product
  • Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)
  • Annual growth rate of current expenditure on health, per capita, in real terms
  • Out-of-pocket expenditure, % of current expenditure on health
  • Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)
  • Physicians, Density per 1000 population (head counts)
  • Nurses, Density per 1000 population (head counts)
  • Total hospital beds, per 1000 population
  • Curative (acute) care beds, per 1000 population
  • Medical technology, Magnetic Resonance Imaging units, total, per million population
  • Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

PMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports_bk_01_01_2020, investor presentations, SEC filings, 10k reports_bk_01_01_2020 and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Market Taxonomy

Drug Type


Route of Administration

Distribution Channel


  • Anti-VEGF
  • Corticosteroids
  • Immunosuppressant
  • Biologics
  • Others
  • Non-infectious Uveitic Macular Edema
  • Diabetic Macular Edema
  • Retinal Vein Occlusion with Macular Edema
  • Oral
  • Parenteral
  • Topical
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • North America
  • Latin America
  • Europe
  • Japan
  • MEA
  • APAC

Companies covered in Non Infectious Macular Edema Treatment Market Report

Company Profiles

  • Allergan, Plc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • F. Hoffman - La Roche Ltd.
  • AbbVie Inc.
  • Bayer AG
  • Valeant Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Clearside Biomedical, Inc.
  • Others.

Non Infectious Macular Edema Treatment Market

Back To Top